简体
  • 简体中文
  • 繁体中文

热门资讯> 正文

OS疗法OST-HER 2显示12个月无事件生存率为35%,与20%的历史对照相比,安全性良好

2025-06-30 18:36

  • The primary endpoint of 12-month Event Free Survival (EFS) for OST-HER2- treated patients (35%) was statistically significant (p= 0.0194) when compared with peer-reviewed comparable historical control (20%)
  • Company also provides regulatory update on comparator for OST-HER2 Phase 2b Trial in the Prevention or Delay of Recurrence in Fully Resected, Lung Metastatic Osteosarcoma
  • Responses to recent FDA Type D Meeting follow-up questions submitted by OS Therapies

风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。